First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial

Jong-Mu Sun, Yee Chao, Sung-Bae Kim, Sun Young Rha, Thomas R Jeffry Evans, Andrew H Strickland, Zev Wainberg, Ian Chau, Sharon Pelles-Avraham, Jaffer Ajani, Ritu Malhotra, Qingyuan Liu, Sijing Li, Edward Cha, Melania Kalaitzidou, Xiayu Huang, Simon Allen, Chih-Hung Hsu

Open source

DOI: 10.1016/s1470-2045(25)00402-4
Published: 2026-01
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00402-4,
  title = {First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial},
  author = {Jong-Mu Sun and Yee Chao and Sung-Bae Kim and Sun Young Rha and Thomas R Jeffry Evans and Andrew H Strickland and Zev Wainberg and Ian Chau and Sharon Pelles-Avraham and Jaffer Ajani and Ritu Malhotra and Qingyuan Liu and Sijing Li and Edward Cha and Melania Kalaitzidou and Xiayu Huang and Simon Allen and Chih-Hung Hsu},
  year = {2026},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(25)00402-4},
  url = {https://doi.org/10.1016/s1470-2045(25)00402-4}
}

RIS

TY  - JOUR
TI  - First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial
AU  - Jong-Mu Sun
AU  - Yee Chao
AU  - Sung-Bae Kim
AU  - Sun Young Rha
AU  - Thomas R Jeffry Evans
AU  - Andrew H Strickland
AU  - Zev Wainberg
AU  - Ian Chau
AU  - Sharon Pelles-Avraham
AU  - Jaffer Ajani
AU  - Ritu Malhotra
AU  - Qingyuan Liu
AU  - Sijing Li
AU  - Edward Cha
AU  - Melania Kalaitzidou
AU  - Xiayu Huang
AU  - Simon Allen
AU  - Chih-Hung Hsu
PY  - 2026
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(25)00402-4
UR  - https://doi.org/10.1016/s1470-2045(25)00402-4
ER  -

APA

Sun, J., Chao, Y., Kim, S., Rha, S. Y., Evans, T. R. J., Strickland, A. H., Wainberg, Z., Chau, I., Pelles-Avraham, S., Ajani, J., Malhotra, R., Liu, Q., Li, S., Cha, E., Kalaitzidou, M., Huang, X., Allen, S., & Hsu, C. (2026). First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(25)00402-4

Source records

crossref · retrieved 2026-09-26T15:00:50.489Z